Author Archives: Patrick J. Halloran, Ph.D., J.D.

Non-obviousness finding for Relistor® OB-listed formulation patent reversed due to structural and functional similarity to prior art compounds

Valeant Pharm. Int., Salix Pharm., Inc. et al. v. Mylan Pharm. Inc., et al., Actavis LLC Docket No. 2018-2097 LOURIE, REYNA, HUGHES April 8, 2020 Brief Summary: DC grant of SJ of non-obviousness of OB formulation patent reversed and remanded … Continue reading

Posted in Generics / ANDA, Obviousness, Obviousness (Secondary Considerations), Obviousness-Teaching Away, Summary Judgment | Leave a comment

Public FDA hearing is a printed publication, Hulu IPR decision does not apply to examination

Ex parte Antonio J. Grillo-Lopez Appeal 2018-006082 (Appln. No. 13/524,837) Precedential (designated April 7, 2020) Brief Summary: Public FDA hearing held to be printed publication and “the framework set forth in the Hulu decision for IPR proceedings does not apply … Continue reading

Posted in Inter Parties Review (IPR), IPR, Public Accessibility | Leave a comment

IPR claim construction of “effective amount” based on prosecution history and obviousness conclusions affirmed; no abuse of discretion in Board’s denial to amend after modifying institution decision

Genentech, Inc. v. Andrei Iancu (USPTO) Docket No. 2019-1263, -1265, -1267, -1270 IPRs 2017-00731, -01121, -02063, -00737, -01122, -01960 LOURIE, MOORE, WALLACH March 26, 2020 Non-Precedential Brief Summary: Board’s claim construction (e.g., “effective amount”), obviousness conclusion and denial of amendment … Continue reading

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Prosecution History Estoppel | Leave a comment

Rejected claim construction proposal during IPR was not prosecution history estoppel, FC affirms infringement under DOE; second infringement decision reversed

Galderma Labs., Nestle Skin Health S.A. et al. v. Amneal Pharm. LLC et al. Docket No. 2019-1021 LOURIE, MOORE, STOLL March 25, 2020 Non-Precedential Brief Summary: DC finding of infringement of certain claims affirmed as statements made in related IPR … Continue reading

Posted in Claim Construction, Doctrine of equivalents, Infringement, Inter Parties Review (IPR), IPR, Prosecution History Estoppel, Uncategorized | Leave a comment

FB improperly joined to its existing IPRs under 315(c); various obviousness conclusions affirmed and vacated

Facebook, Inc. v. Windy City Innovations, LLC Docket No. 2018-1400-3, -1537, -1540-41 (IPR2016-00=1156-59, IPR2017-00659, -00709 PROST, PLAGER, O’MALLEY March 18, 2020 Brief Summary: Board improperly joined FB as a party to its own existing IPRs under section 315(c); various obviousness … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

IPR decision of obviousness of method of treatment claim reversed for erroneous claim construction

Kaken Pharm. Co., Inc., Bausch Health Cos. Inc. v. USPTO Docket No. 2018-2232 (IPR2017-00190, -01429) NEWMAN, O’MALLEY, TARANTO March 13, 2020 Brief Summary: IPR obviousness decision reversed based on erroneous claim construction in method of treatment claim. Summary: Kaken appealed … Continue reading

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Uncategorized | Leave a comment

DC patent ineligibility holding for Illumina’s fetal DNA-related claims reversed

Illumina, Inc., Sequenom, Inc. v. Ariosa Diagnostics, Inc. et al. Docket No. 2019-1419 LOURIE, MOORE, REYNA March 17, 2020 Brief Summary: DC finding that Illumina’s fetal DNA-related claims are patent ineligible reversed. Summary: Illumina appealed DC decision finding certain claims … Continue reading

Posted in Patent Eligibility (101), Patentability, Uncategorized | Leave a comment